How to Test Human-Specific Combination Immunotherapies In Vivo

Por um escritor misterioso

Last updated 16 setembro 2024

How to Test Human-Specific Combination Immunotherapies In Vivo

Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.

Beginners Guide to PBMC Humanized Tumor Models

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial - eBioMedicine

Cancer vaccines: the next immunotherapy frontier

In vitro functional assays to augment immunotherapy research

Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy: Molecular Therapy - Methods & Clinical Development

In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer - ScienceDirect

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity

Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer Immunotherapy - Yang - 2023 - Advanced Science - Wiley Online Library

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma

Frontiers Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More

What Are Neoantigens?

Frontiers CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma

A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases - eBioMedicine

Recomendado para você